PharVision Advisers’s Nutrien NTR Stock Holding History

PharVision Advisers’s Portfolio NTR Stock Details NTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-6,345	Closed	-$373K	–	906
2025 Q3	$373K	Buy	+6,345	New	+$370K	0.21%	109

Other funds holding NTR

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $123B AUM 34.51% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

PharVision Advisers's NTR Position: Q4 2025 in Review

PharVision Advisers sold out of Nutrien (NTR) in Q4 2025, closing a stake of 6,345 shares — an estimated $373K sold.

PharVision Advisers first reported a position in NTR in Q3 2025 and held it in 1 quarter. The position peaked at $373K in Q3 2025. 666 funds tracked by Wall St. Rank hold NTR as of Q4 2025.

PharVision Advisers reported no remaining Nutrien position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 6,345 Nutrien shares in Q4 2025, an estimated $373K.
PharVision Advisers first reported a position in Nutrien in Q3 2025 and held it in 1 quarter.
PharVision Advisers's Nutrien position peaked at $373K in Q3 2025.
666 funds tracked by Wall St. Rank held Nutrien as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.